@article {Maioli:2010:1389-2002:425,
title = "Rottlerin: Bases for a Possible Usage in Psoriasis",
journal = "Current Drug Metabolism",
parent_itemid = "infobike://ben/cdm",
publishercode ="ben",
year = "2010",
volume = "11",
number = "5",
publication date ="2010-06-01T00:00:00",
pages = "425-430",
itemtype = "ARTICLE",
issn = "1389-2002",
url = "https://www.ingentaconnect.com/content/ben/cdm/2010/00000011/00000005/art00004",
doi = "doi:10.2174/138920010791526097",
keyword = "Rottlerin, Inflammation, Angiogenesis, NFκB, Proliferation",
author = "Maioli, Emanuela and Valacchi, Giuseppe",
abstract = "Rottlerin is a natural polyphenolic compound, which was initially indicated and marketed as a PKC inhibitor and recently proposed and patented as an anti-hypertensive drug. In vitro results from our Laboratory and data from the literature suggest a potential use of Rottlerin in the treatment/control of psoriasis, a skin disease characterized by abnormal cellular proliferation, abnormal angiogenesis and inflammation. Rottlerin, indeed, is an antioxidant and a potent inhibitor of the transcription factor NFB, a key mediator of immune responses and a crucial regulator of cell cycle and apoptosis in immune cells, endothelial cells and keratinocytes. Herein, we will review the multiple activities of Rottlerin (antioxidant, antiproliferative, antiangiogenic and anti-inflammatory) that give to the drug the potential to be used as a new therapeutic approach against psoriasis. ",
}